PRIMARY IMMUNE DEFICIENCY TREATMENT FOUNDATION

a Delaware Nonprofit Nonstock Corporation

POLICY REGARDING INDIRECT SUPPORT FOR PIDTF SUPPORTED RESEARCH

The Board of Directors of the Primary Immune Deficiency Treatment Foundation has determined it to be essential to support the research efforts of investigators performing research related to inborn errors of immunity, other immunologic conditions, or research that improves the lives of humans. The Primary Immune Deficiency Treatment Foundation is a charitable entity.  This policy provides guidance regarding funding of indirect costs related to the support of approved research activities.

The Primary Immune Deficiency Treatment Foundation does not support indirect costs. 

The Primary Immune Deficiency Treatment Foundation defines indirect costs as:

·       Overhead expenses or operational costs incurred by the applicant’s organization that support the organization’s activities, but that are not easily identified with any specific project.  

·       Administrative or other expenses which are not directly allocable to a specific activity or project.

·       Expenses related to general operations of an organization that are shared among projects and/or functions.

·       Examples include but are not limited to facilities costs, accounting, grants management, legal expenses, utilities, and technology support.